RxDoctor Payments Data

Eric Wechsler, MD

Nephrology · Newport Beach, CANPI 1659469526

Payments from drug & device makers

$36,074in general payments, 2019–2025

Across 584 payments — averaging $61.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$14K
  • GSK$11K
  • AstraZeneca$1K
  • Vifor Pharma, Inc.$1K
  • Otsuka America Pharmaceutical, Inc.$940
  • Bayer$635
  • plus $7K from 39 others

What the payments were for

  • Consulting fees$10,40029%
  • Speaking & faculty fees$11,27631%
  • Travel & lodging$1,9745%
  • Food & beverage$12,20434%
  • Education$2201%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$36,074 in reported general payments places this provider in the 85th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$464,169
Medicare patients
936
Services billed
2,915

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol299$326,275
FilspariSparsentan20$212,401
Tolvaptan15$64,429
LokelmaSodium Zirconium Cyclosilicate47$49,439
JardianceEmpagliflozin32$42,754
DapagliflozinDapagliflozin Propanediol67$41,619
OzempicSemaglutide28$35,123
KerendiaFinerenone31$34,164
VeltassaPatiromer Calcium Sorbitex31$30,154
MounjaroTirzepatide20$25,854
Droxidopa14$20,214
VascepaIcosapent Ethyl43$16,827
EdarbiAzilsartan Medoxomil30$15,186
Nebivolol Hcl138$9,809
EntrestoSacubitril/Valsartan12$9,279

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$1,471$375,714346 claims
Travere Therapeutics, Inc.Filspari$171$212,40120 claims
Boehringer IngelheimJardiance$565$42,75432 claims
Novo NordiskOzempic$360$35,12328 claims
BayerKerendia$635$34,16431 claims
Lilly USA, LLCMounjaro$33$25,85420 claims
Arbor Pharmaceuticals, Inc.Edarbi$89$15,18630 claims
NovartisEntresto$348$9,27912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,341 nephrology providers in California.

Other nephrology in Newport Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →